

In response to the Requirement for Restriction dated January 23, 2003, having a shortened statutory period for response set to expire February 23, 2003, kindly enter the following response:

Restriction to one of the following inventions has been required under 35 USC 121:

- I. Claims 1-2, in so far as they are drawn a biopolymer marker of SEQ ID NO: 1, classified in class 530, subclass 300, for example.
- II. Claims 1-2, in so far as they are drawn a biopolymer marker of SEQ ID NO: 2, classified in class 530, subclass 300, for example.
- III. Claims 1-2, in so far as they are drawn a biopolymer marker of SEQ ID NO: 3, classified in class 530, subclass 300, for example.
- IV. Claims 3-9, in so far as they are drawn to a method for evidencing a disease by evidencing a biopolymer marker of SEQ ID NO: 1, classified in class 424, subclass 86, for example.
- V. Claims 3-9, in so far as they are drawn to a method for evidencing a disease by evidencing a biopolymer marker of SEQ ID NO: 2, classified in class 424, subclass 86, for example.
- VI. Claims 3-9, in so far as they are drawn to a method for evidencing a disease by evidencing a biopolymer maker of SEQ ID NO: 3, classified in class 424, subclass 86, for example.
- VII. Claims 10-28, in so far as it is drawn to a diagnostic kit for determining the presence of the biopolymer of SEQ ID NO: 1, classified in class 424, subclass 130.1, for example.
- VIII. Claims 10-28, in so far as it is drawn to a diagnostic kit for determining the presence of the biomarker of SEQ ID NO: 2, classified in class 424, subclass 130.1, for example.

- IX. Claims 10-28, in so far as it is drawn to a diagnostic kit for determining the presence of the biomarker of SEQ ID NO: 3, classified in class 424, subclass 130.1, for example.
- X. Claims 29-32, in so far as they are drawn to an antibody that binds a biopolymer marker of SEQ ID NO: 1, classified in class 530, subclass 397.1, for example.
- XI. Claims 29-32, in so far as they are drawn to an antibody that binds a biopolymer marker of SEQ ID NO: 2, classified in class 530, subclass 397.1, for example.
- XII. Claims 29-32, in so far as they are drawn to an antibody that binds a biopolymer marker of SEQ ID NO: 3, classified in class 530, subclass 397.1, for example.
- XIII. Claims 33-37, in so far as they are drawn to a process for identifying therapeutic avenues by using a biopolymer marker of SEQ ID NO: 1, classified in class 435, subclass 7.1, for example.
- XIV. Claims 33-37, in so far as they are drawn to a process for identifying therapeutic avenues by using a biopolymer marker of SEQ ID NO: 2, classified in class 435, subclass 7.1, for example.
- XV. Claims 33-37, in so far as they are drawn to a process for identifying therapeutic avenues by using a biopolymer marker of SEQ ID NO: 3, classified in class 435, subclass 7.1, for example.
- XVI. Claim 38, in so far as it is drawn to a process for regulating a disease state by controlling the presence or absence of a biopolymer marker of SEQ ID NO: 1, classified in class undetermined, subclass undetermined, for example.
- XVII. Claim 38, in so far as it is drawn to a process for regulating a disease state by controlling the presence or absence of a biopolymer marker of SEQ ID NO: 2, classified in class undetermined, subclass undetermined, for example.
- XVIII. Claim 38, in so far as it is drawn to a process for regulating a disease state by controlling